Filing Flows

Filing Flows › Companies › Nautilus Biotechnology › Cash flow

Nautilus Biotechnology cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$14.7M in Q3 2026 · −$55.1M over twelve months

Operating cash flow−$13.3M
Capital spending−$1.4M
Free cash flow−$14.7M

Analysis

In Q3 2026, Nautilus Biotechnology generated −$13.3M of operating cash flow and spent $1.4M on capital projects, leaving free cash flow of −$14.7M. That is $3.3M less than in Q3 2025 (−$11.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$52.5M; the largest uses were operating cash flow ($52.5M), capital spending ($2.7M); besides operations, cash came from other investing ($40.1M), shares issued ($1.3M); the cash balance fell by $13.5M.

Operating cash flow was −$13.3M against net income of −$15.6M. The largest differences: stock-based pay +$1.3M, accrued liabilities +$690K, depreciation & amortization +$200K.

Free cash flow

Nautilus Biotechnology: free cash flow by quarterNautilus Biotechnology: free cash flow by quarter−$14.6MQ4 2024−$14.2MQ1 2025−$13.7MQ2 2025−$11.5MQ3 2025−$12.6MQ4 2025−$13.6MQ1 2026−$14.2MQ2 2026−$14.7MQ3 2026
Operating cash flow less capital spending.
Nautilus Biotechnology: operating cash flow against capital spendingNautilus Biotechnology: operating cash flow against capital spendingOperating cash flowCapital spending−$14.3M$254KQ4 2024−$13.9M$219KQ1 2025−$13.3M$396KQ2 2025−$11.0M$418KQ3 2025−$12.4M$244KQ4 2025−$13.1M$510KQ1 2026−$13.7M$454KQ2 2026−$13.3M$1.4MQ3 2026
Latest (Q3 2026): Operating cash flow −$13.3M, Capital spending $1.4M.

Capital allocation, year by year

Nautilus Biotechnology: where the cash came from (up) and went (down), by fiscal yearNautilus Biotechnology: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$39.2MFY2021: Shares issued $167KFY2021: Capital spending −$2.3M$167KFY2021FY2022: Operating cash flow −$45.8MFY2022: Shares issued $330KFY2022: Capital spending −$2.3M$330KFY2022FY2023: Operating cash flow −$51.7MFY2023: Shares issued $104KFY2023: Capital spending −$2.4M$104KFY2023FY2024: Operating cash flow −$59.1MFY2024: Shares issued $620KFY2024: Capital spending −$2.1MFY2024: Acquisitions −$760K$620KFY2024FY2025: Operating cash flow −$50.7MFY2025: Shares issued $58KFY2025: Capital spending −$1.3M$58KFY2025
Over these 5 years operating cash flow totalled −$247M; the largest uses were operating cash flow ($247M) and capital spending ($10.4M). Cash-flow statements as filed.

Where the cash came from and went

Nautilus Biotechnology: sources (+) and uses (−) of cash, Q3 2026Nautilus Biotechnology: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$13.3MOther investing$11.9MCash drawn (+) / kept (−)$2.8MCapital spending−$1.4MShares issued$26K
Nautilus Biotechnology: sources (+) and uses (−) of cash, TTM to Q3 2026Nautilus Biotechnology: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$52.5MOther investing$40.1MCash drawn (+) / kept (−)$13.5MCapital spending−$2.7MShares issued$1.3MOther financing$211K

From profit to cash

Nautilus Biotechnology: net income to operating cash flow, Q3 2026Nautilus Biotechnology: net income to operating cash flow, Q3 2026Net income−$15.6MDepreciation & amortization$200KStock-based pay$1.3MPayables$152KAccrued liabilities$690KPrepaid and other assets−$29KOperating cash flow−$13.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$13.3M−$1.4M$26K$2.8M−$14.7M
Q2 2026−$13.7M−$454K$102K$1.5M−$14.2M
Q1 2026−$13.1M−$510K$1.1M−$2.2M−$13.6M
Q4 2025−$12.4M−$244K$32K$11.5M−$12.6M
Q3 2025−$11.0M−$418K—$10.6M−$11.5M
Q2 2025−$13.3M−$396K$8K−$1.2M−$13.7M
Q1 2025−$13.9M−$219K$18K−$5.6M−$14.2M
Q4 2024−$14.3M−$254K$205K−$23.2M−$14.6M

Nautilus Biotechnology: income statement and cash flow

Nautilus Biotechnology, Q3 2026: revenue $234K. The chart follows the revenue to costs, profit and cash.

Nautilus Biotechnology: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.